New drug aims to tame rare immune storms
NCT ID NCT04641442
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests a drug called MAS825 in 17 people with rare genetic conditions that cause severe inflammation. The goal is to see if the drug can prevent disease flares better than a placebo. Participants will be monitored for safety and effectiveness over several periods.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MAS825
What this could lead to
If successful, this could provide a new treatment option to control flares in rare, severe autoinflammatory diseases.
What could go wrong
This is a small early-phase trial with only 17 participants, so results may not apply broadly. The drug may not prevent flares or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NLRC4-GOF, AIFEC (AUTOINFLAMMATION WITH INFANTILE ENTEROCOLITIS), XIAP DEFICIENCY, CDC42 MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bambino Gesu Hospital
Roma, RM, 00165, Italy
-
Centrum detske revmatologie a autoinflamatornich onemocneni
Prague, CZ, 121 00, Czechia
-
Children´s Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
-
Novartis Investigative Site
Prague, 128 08, Czechia
-
Novartis Investigative Site
Paris, 75970, France
-
Novartis Investigative Site
Chiba, 266-0007, Japan
-
Novartis Investigative Site
Madrid, 28046, Spain
-
Novartis Investigative Site
London, NW3 2QG, United Kingdom
-
Seattle Children´s Hospital
Seattle, Washington, 98105, United States
-
Texas Children´s Hospital
Houston, Texas, 77030, United States
-
Ustav Imunologie 2 LF UK a FN Motol
Prague, 150 06, Czechia